Endoscopic management and follow-up of bleeding Dieulafoy’s lesions
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S357-S358
DOI: 10.1055/s-0044-1783577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von B. Aabdi und 5 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Aims
Dieulafoy’s lesion (DL), defined as a vascular abnormality of the gastrointestinal (GI) tract, is a rare cause of active, recurrent, and unexplained gastrointestinal (GI) bleeding. DL may be responsible for 1% to 2% of all acute GI hemorrhage and up to 6% of non-variceal GI bleeding. Stomach, is by far the most common site of DL. We investigate retrospectively the clinical and endoscopic features and we review the effectiveness of endoscopic management of bleeding DLs. We also aimed to identify recurrence and mortality rate in our endoscopic unit.
Methods
The findings from 1170 patients who had emergency endoscopy for acute gastrointestinal bleeding at our endoscopic department between January 2018 and August 2023 were retrospectively analyzed. Demographic, clinical and endoscopic data of bleeding DL were collected. Furthermore, we investigate factors of re-bleeding and mortality following endoscopy.
Results
Only seven cases presented with Dieulafoy’s lesion (DL). The median age of these patients was 74 years, with a male-to-female ratio of 2.5. Only anticoagulant and antiplatelet agents were significantly associated with (DLs). Gastric and duodenal locations were predominant. All patients were presented with GI bleeding as their initial symptom. Initial hemostasis was obtained in all patients treated respectively by epinephrine injection (16%), Argon plasma coagulation (APC) (33%) and by combined therapy (50%). There were no complications related to endoscopic therapy. [ 1 ] [ 2 ] [ 3 ] Among the patients treated solely with an epinephrine injection or argon plasma coagulation (APC), two out of three (66%) experienced early recurrence (within 72 hours). In contrast, among the 3 patients who received combined therapy, only one case experienced late recurrence during the follow-up period, (average duration of one year). Pathological diagnosis was necessary in one case. One patient (14%) died of hemorrhagic shock during the same hospitalization. Average length of hospital stay was 3 days.
Conclusions
Thanks to the emergence of endoscopic therapies, the recurrence rate has decreased and the prognosis has highly improved. It is concluded that the endoscopic approach should be considered as the first choice to manage bleeding DLs. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Aabdi, B., Ghizlane, K., Zazour, A., Koulali, H., Elmqaddem, O., & Ismaili, Z. (2024). Endoscopic management and follow-up of bleeding Dieulafoy’s lesions. Endoscopy, 56(S 02 S 02), S357-S358. https://doi.org/10.1055/s-0044-1783577
Vancouver
Aabdi B, Ghizlane K, Zazour A, Koulali H, Elmqaddem O, Ismaili Z. Endoscopic management and follow-up of bleeding Dieulafoy’s lesions. Endoscopy. 2024;56(S 02 S 02):S357-S358. doi:10.1055/s-0044-1783577
BibTeX
@article{Aabdi2024,
author = {Aabdi, B. and Ghizlane, K. and Zazour, A. and Koulali, H. and Elmqaddem, O. and Ismaili, Z.},
title = {Endoscopic management and follow-up of bleeding Dieulafoy’s lesions},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S357--S358},
doi = {10.1055/s-0044-1783577}
}
EUVIMED